The Charlotte, North Carolina-based bank allocates more than $2 billion annually for healthcare benefits covering its approximately 211,000 employees. According to figures shared by Moynihan, GLP-1 medications now account for roughly 13% of the company's total healthcare spending, highlighting how rapidly demand for the drugs has grown. Across corporate America, employers have wrestled with whether to continue covering weight loss drugs as utilization has surged. Rather than limiting access, the bank combines coverage for GLP-1 medications with health coaching programs that help employees manage weight loss, improve nutrition and make long-term lifestyle changes. The CEO also pointed to emerging research suggesting that GLP-1 drugs may provide benefits beyond weight reduction.